<DOC>
	<DOCNO>NCT01412333</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy , parallel-group study evaluate efficacy safety ocrelizumab comparison Rebif ( interferon beta-1a ) participant relapse multiple sclerosis . Participants randomize receive either Group A , ocrelizumab 600 milligram ( mg ) intravenously ( IV ) every 24 week plus Rabif placebo subcutaneously ( SC ) 3 time weekly , , Group B , Rebif 8.8 microgram ( mcg ) ( Weeks 1 2 ) , 22 mcg ( Weeks 3 4 ) , 44 mcg ( Week 5 thereafter ) SC 3 time weekly plus ocrelizumab placebo IV every 24 week . Planned duration double-blind treatment 96 week . Participants complete 96-week double-blind treatment option enter single group , active treatment open label extension , provide fulfill eligibility criterion .</brief_summary>
	<brief_title>A Study Ocrelizumab Comparison With Interferon Beta-1a ( Rebif ) Participants With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Diagnosis multiple sclerosis , accordance revise McDonald criterion ( 2010 ) At least 2 documented clinical attack within last 2 year prior screen one clinical attack year prior screen ( within 30 day prior screen ) Neurologic stability great equal ( &gt; /= ) 30 day prior screen baseline Expanded Disability Status Scale ( EDSS ) score 0 5.5 inclusive Primary progressive multiple sclerosis Disease duration 10 year patient EDSS score less equal ( &lt; /= ) 2.0 screen Contraindications MRI Known presence neurological disorder may mimic multiple sclerosis Pregnancy lactation Requirement chronic treatment systemic corticosteroid immunosuppressant course study History currently active primary secondary immunodeficiency History severe allergic anaphylactic reaction humanize murine monoclonal antibody Active infection , history know presence recurrent chronic infection ( example , hepatitis B C , Human Immunodeficiency Virus [ HIV ] , syphilis , tuberculosis ) History progressive multifocal leukoencephalopathy Contraindications intolerance oral IV corticosteroid Contraindications Rebif incompatibility Rebif use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>